Watchlist Price Alert

Acurx Pharmaceuticals Inc... (ACXP)

NASDAQ: ACXP · Real-Time Price · USD

0.34

-0.06 (-15.17%)

At close: May 06, 2025, 3:59 PM

0.36

4.71%

After-hours: May 06, 2025, 07:38 PM EDT

-15.17% (1D)

Bid	0.34
Market Cap	7.62M
Revenue (ttm)	n/a
Net Income (ttm)	-2.83B
EPS (ttm)	-0.87
PE Ratio (ttm)	-0.39
Forward PE	-0.45
Analyst	Buy

Ask	0.36
Volume	75,352
Avg. Volume (20D)	252,080
Open	0.39
Previous Close	0.40
Day's Range	0.34 - 0.39
52-Week Range	0.30 - 3.33
Beta	-1.37

About ACXP

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bac...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 25, 2021

Employees 4

Stock Exchange NASDAQ

Ticker Symbol ACXP

Website https://www.acurxpharma.com

Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for ACXP stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 3429.41% from the latest price.

Stock Forecasts

Why Price Moved

2 months ago

-29.86%

Acurx Pharmaceuticals shares are trading lower aft... Unlock content with Pro Subscription

4 months ago

-26.01%

Acurx Pharmaceuticals shares are trading lower after the company announced a $2.5 million registered direct offering.

News

4 weeks ago · zacks.com

Acurx Pharmaceuticals (ACXP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Acurx Pharmaceuticals (ACXP), indicating that the stock has found support. This, combined with an upward trend in earnings es...

1 month ago · zacks.com

Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's What You Should Know

Acurx Pharmaceuticals (ACXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago · seekingalpha.com

Acurx Pharmaceuticals, Inc. (ACXP) Q4 2024 Earnings Call Transcript

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q4 2024 Earnings Conference Call March 18, 2025 8:00 AM ET Company Participants Robert Shawah - Co-Founder and Chief Financial Officer David Luci - President...